Aura Biosciences (AURA) investor relations material

Innovation and clinical development

• Developing a novel class of virus-like drug conjugates (VDCs) for targeted cancer therapy in ocular and urologic oncology.

• Lead candidate AU-011 (bel-sar) is in late-stage clinical trials for early choroidal melanoma, with a SPA agreement supporting registration.

• Additional indications in ocular oncology (metastasis to the choroid, ocular surface cancers) are advancing through phase 2 and phase 1 trials.

• VDCs offer high selectivity, potent tumor ablation, and immune activation, with low risk of resistance.

• Platform potential extends to both ocular and non-ocular solid tumors.

Key milestones and financial outlook

• Next milestones include completion of phase 3 enrollment for choroidal melanoma and data from the bladder cancer study.

• Cash runway extends into the first half of 2027, supporting ongoing and planned clinical programs.

• Ocular oncology pipeline targets over three indications, all addressable with the same VDC technology.

Ocular oncology opportunity

• Ocular oncology represents a rare disease market with 66,000 patients lacking effective treatments.

• VDCs can treat multiple ocular cancers with a single technology, aiming to replace surgery and radiotherapy.

• Early choroidal melanoma patients currently face limited options, often resorting to watchful waiting or radiotherapy with high comorbidities.

• VDC therapy offers a non-invasive, vision-preserving alternative, aiming to disrupt the current standard of care.

• Phase 2 data show 80% tumor control and 90% vision preservation at 12 months, supporting high probability of phase 3 success.